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Abstract: Uveitis is an inﬂ  ammatory, putative Th1-mediated autoimmune disease that affects 
various parts of the eye and is a leading cause of visual loss. Currently available therapies are 
burdened with toxicities and/or lack deﬁ  nitive evidence of efﬁ  cacy. Voclosporin, a rationally 
designed novel calcineurin inhibitor, exhibits a favorable safety proﬁ  le, a strong correlation 
between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The 
LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical 
development program was initiated in 2007 to assess the safety and efﬁ  cacy of voclosporin for 
the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE 
is successful, voclosporin will become the ﬁ  rst Food and Drug Administration-approved 
corticosteroid-sparing agent for this condition.
Keywords: voclosporin, calcineurin inhibitors, LX211, LUMINATE trials, ophthalmic diseases, 
uveitis, ISA247
Introduction
Uveitis, an inﬂ  ammatory, Th1-mediated autoimmune disease affecting various parts of 
the eye, is a signiﬁ  cant cause of visual loss. The condition accounts for 2.8% to 10% of 
all cases of blindness, including approximately 30,000 new cases of legal blindness in 
the United States each year (Nussenblatt 1990; Gritz and Wong 2004). A recent report 
estimates the incidence of uveitis at more than 50 cases per 100,000 person-years, with 
a prevalence of 115 per 100,000 persons (Gritz and Wong 2004).
Corticosteroids (topical, systemic, locally injected, or corticosteroid-eluting 
implants) are the current mainstay of therapy and the only Food and Drug Administra-
tion (FDA)-approved treatment for uveitis. Although often highly effective, chronic 
corticosteroid use, whether administered systemically or locally, is burdened with well-
known, serious adverse events (AEs) including osteoporosis, metabolic disturbances, 
diabetogenicity and obesity, elevated blood pressure, and impaired wound healing. 
A number of currently available immunosuppressive agents (eg, antimetabolites, T-cell 
inhibitors, alkylating agents) are commonly employed as steroid-sparing therapies; 
however, randomized controlled clinical trials on the use of these agents in uveitis 
patients are broadly lacking (Jabs and Karamursel 2005). Moreover, many of these 
agents are associated with signiﬁ  cant, serious AEs. Therefore, immunosuppressive 
agents with proven efﬁ  cacy and an acceptable safety proﬁ  le are a much needed addition 
to the therapeutic armamentarium for the management of this serious disease.Clinical Ophthalmology 2008:2(4) 694
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Voclosporin
Description/mechanism of action
Voclosporin (Lux Biosciences, Inc. Jersey City, NJ) is a 
rationally designed novel calcineurin inhibitor (Isotechnika, 
Inc., 2008) currently in phase 2/3 clinical development 
for noninfectious uveitis. The inventor of the compound, 
Isotechnika, Inc., (Edmonton, Canada), is concurrently 
developing the drug for plaque psoriasis and the prevention 
of allograft rejection (No authors listed 2007).
Voclosporin is a next-generation calcineurin inhibitor. 
Calcineurin inhibitors are potent immunosuppressants that 
reversibly inhibit T-cell proliferation and prevent release of 
proinﬂ  ammatory cytokines by blocking the activity of the 
calcium-regulated serine-threonine phosphatase calcineurin, 
an enzyme found in cell cytoplasm (Schreiber and Crabtree 
1992; Dumont 1996). Calcineurin inhibitors also block lym-
phokine production and release, ﬁ  broblast proliferation, and 
vascular endothelial growth factor expression (Dumont 1996; 
Ho et al 1996; Cho et al 2002). After entering the lymphocyte, 
calcineurin inhibitors bind intracellularly to immunophilins 
and form complexes that subsequently bind to and inhibit 
calcineurin (Schreiber and Crabtree 1992; Stalder et al 
2003). This process prevents translocation to the nucleus of 
the cytoplasmic component of the nuclear factor of activated 
T cells (NFAT), which in turn impairs transcription of the 
genes encoding interleukin-2 (IL-2) and other lymphokines 
(Schreiber and Crabtree 1992; Ho et al 1996).
Voclosporin was developed by modification of the 
functional group on the amino acid residue at position 1 of 
the cyclosporin A (CsA) molecule (Figure 1) (Dumont 2004). 
The result is a more predictable pharmacokinetic proﬁ  le than 
that of CsA (Yatscoff et al 2002; Abel et al 2003; Wasel et al 
2006) and an approximately 4-fold greater inhibitory potency 
as measured by the in vitro calcineurin inhibition assay. (Abel 
et al 2004; Aspeslet et al 2004). Results of phase 1, phase 2, 
and phase 3 clinical trials indicate that voclosporin exhib-
its a well correlated pharmacokinetic/pharmacodynamic 
(PK/PD) relationship (Figures 2–3) (Yatscoff et al 2002; 
Abel et al 2003; Wasel et al 2006). The utility of systemically 
administered voclosporin for the prevention and treatment 
of experimental autoimmune uveoretinitis (EAU) in rats has 
been reported recently (Cunningham et al 2007).
Clinical trials with voclosporin
The PK/PD proﬁ  le of voclosporin has been evaluated in six 
phase 1 studies in healthy volunteers. Doses in single-dose 
studies ranged from 0.25 mg/kg to 4.5 mg/kg, and in 
multiple-dose studies, from 0.25 mg/kg bid to 1.5 mg/kg bid. 
Voclosporin exhibited good bioavailability, rapid absorption 
(median time to maximum [Tmax]   2 hours), and ﬁ  rst-order 
pharmacokinetics indicated by linear increases in area 
under the curve (AUC) and maximum concentration (Cmax) 
as a function of dose. Whole blood concentration proﬁ  les 
indicated multiphasic elimination after 24 hours. In a 
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Figure 1 Comparison of structures of voclosporin (left) and cyclosporin A (right).Clinical Ophthalmology 2008:2(4) 695
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multiple-dose study of 0.25 mg/kg and 0.5 mg/kg bid for 
10 days, the T1/2 was 6.9 to 7.8 hours on Day 1 and 30.1 
to 33.2 hours on Day 13, indicating an approximate 4-fold 
accumulation of voclosporin whole blood levels on Day 13 
(Isotechnika, Inc., 2008).
Voclosporin undergoes extensive first-pass hepatic 
metabolism via hydroxylation and N-demethylation reactions 
to active metabolites. Cytochrome P450 3A4/5 acts as the 
primary enzyme involved in phase I of the metabolism of 
voclosporin (Freitag et al 2006; Isotechnika, Inc., 2008). 
Voclosporin inhibits the activity of P450 3A4, but not 
CYP2D6 or CYP2C9. Based on animal studies, fecal 
excretion is the primary route of elimination. voclosporin 
should be taken on an empty stomach to ensure adequate 
drug concentration, based on results of a pharmacokinetic 
study that indicate a food effect on the rate and extent of drug 
absorption (Isotechnika, Inc., 2008).
Results of phase 1 trials indicate that the pharmacodynamic 
ability of voclosporin to inhibit calcineurin appears to be dose-
proportional up to a maximum of 1 mg/kg bid for 10 days, 
after which the degree of inhibition plateaus (Isotechnika, Inc., 
2008). The efﬁ  cacy of voclosporin in organ transplantation 
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Figure 2 Comparison of calcineurin inhibition of voclosporin versus CsA.
Abbreviations:  AIC, Akaike information criterion; CsA, cyclosporin A; Emax, maximal effect.
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Figure 3 Emax versus reduction in PASI in phase 3 psoriasis study.
Abbreviations: CNi, calcineurin inhibition; Emax, maximal effect; PASI, Psoriasis Area and Severity Index.Clinical Ophthalmology 2008:2(4) 696
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and psoriasis has been reported and is indicative of the 
potential scope of the compound in the treatment of immune 
disorders, including noninfectious uveitis.
In a phase 2a, 12-week, randomized, multicenter, 
open-label study, the primary endpoints of a low incidence 
of acute rejection and stable kidney function were main-
tained in 132 stable, post–renal transplant patients who 
were switched from CsA (Neoral®) to voclosporin (Yatscoff 
et al 2003; Dumont 2004). Further, voclosporin produced a 
level of immunosuppression comparable to CsA at 33% of 
the blood drug concentration. Strong correlations were seen 
between C0 (concentration of drug in plasma at the time 
of an instantaneous intravenous injection of a drug that is 
instantaneously distributed to its volume of distribution) and 
both AUC and calcineurin inhibition for voclosporin, but not 
for CsA (Figure 2).
A 24-week, randomized, open-label, phase 2b trial in 
de novo renal transplant patients to compare the efﬁ  cacy 
and safety of voclosporin and tacrolimus has recently 
completed enrollment. Starting doses were 0.4, 0.6, and 
0.8 mg/kg bid for voclosporin and 0.05 mg/kg bid for 
tacrolimus, with doses titrated to target trough concentrations 
(Gaston et al 2006). In a recent safety update of the 
ﬁ  rst 116 patients who completed ∼4 months of therapy 
(range, 3.7 ± 2.2 to 4.5 ± 2.2 months), similar efﬁ  cacy, 
as measured by biopsy-proven acute rejection episodes, 
was demonstrated between the two agents, as well as an 
acceptable safety proﬁ  le. Excellent renal function was noted 
in all voclosporin dose groups (Busque et al 2007).
In a 24-week randomized trial in 451 patients with 
moderate to severe plaque psoriasis, a statistically signiﬁ  cant 
difference for voclosporin vs placebo was seen at weeks 
12 and 24 in the Psoriasis Area and Severity Index (PASI 75) 
response, as well as a 2-point reduction in the Static Global 
Assessment score (Gupta et al 2006; Langley et al 2006). 
Patients received placebo or voclosporin (0.2 mg/kg, 
0.3 mg/kg, or 0.4 mg/kg bid) for 12 weeks, after which the 
placebo group was switched to voclosporin 0.3 mg/kg bid. 
Drug concentration was highly correlated with calcineurin 
inhibition (r = 0.79), and percent calcineurin inhibition was 
highly correlated with mean percent reduction in the efﬁ  cacy 
endpoint (PASI; r = 0.86), illustrating the strong PK/PD 
correlation of voclosporin (Figure 3) (Gupta et al 2006).
Clinical safety of voclosporin
Voclosporin was well tolerated and safe in all single- and 
multiple-dose phase 1 trials in dosages up to 4.5 mg/kg, and in 
phase 2 and phase 3 trials in renal transplantation and psoriasis 
patients (Aspeslet et al 2001, 2004; Dumont 2004; Gaston 
et al 2006; Guenther et al 2006; Isotechnika, Inc., 2007a; No 
authors listed 2007). In phase 2 and 3 trials, the most common 
AEs, typically of low frequency and mild severity, were diar-
rhea, headache, and hypertension (Yatscoff et al 2003; Gaston 
et al 2006; Guenther et al 2006). These events appeared to 
be dose-dependent. No signiﬁ  cant changes in levels of cho-
lesterol, triglycerides, or other biochemical parameters, or in 
new-onset diabetes or infectious complications, have been 
reported in studies to date.
Renal function, assessed by creatinine clearance, 
remained stable in patients in clinical trials, with few 
experiencing clinically signiﬁ  cant changes. Speciﬁ  cally, in 
the phase 3 study in psoriasis, the highest mean change in 
serum creatinine in any dosing group (0.2, 0.3, or 0.4 mg/kg 
bid) at week 12 was 5.6% above baseline, which is considered 
to be within normal analytic and physiologic variation 
(Langley et al 2006; Isotechnika, Inc., 2007b; No authors 
listed 2007). A total of 5 patients (4 [4%] in the high-dose and 
1 [1%] in the mid-dose group) withdrew due to a clinically 
signiﬁ  cant decrease in kidney function (No authors listed 
2007) At 24 weeks, there were no clinically signiﬁ  cant 
changes in mean serum creatinine or glomerular ﬁ  ltration 
rate (GFR), but 5 (2%) patients withdrew due to changes 
in renal function (30% decrease in GFR conﬁ  rmed) (Papp 
et al 2004). After 60 weeks, mean serum creatinine remained 
stable, with clinically signiﬁ  cant changes in kidney function 
occurring in 4% of patients (Isotechnika, Inc., 2007b).
Therapeutic window of voclosporin
These safety data, combined with a predictable PK/PD 
relationship, suggest a broad therapeutic window for 
voclosporin. This is in stark contrast to the narrower 
therapeutic ranges of other calcineurin inhibitors, such as 
CsA and tacrolimus, which may require the use of therapeutic 
drug monitoring to correlate the parent substance and its 
metabolites with important clinical parameters (Staatz and 
Tett 2004; Vollenbroeker et al 2005). Voclosporin achieved 
a clinically relevant range of calcineurin inhibition (40% 
to 70%) in phase 1 and 2a trials. Within this therapeutic 
range, no signiﬁ  cant changes in creatinine clearance, mean 
arterial blood pressure, or serum magnesium levels have 
been observed. An effect of voclosporin on creatinine 
clearance has only been observed at a drug exposure  100% 
of that required to achieve 70% calcineurin inhibition 
(2250 vs 900 ng*h/mL) (Yatscoff et al 2002). More recent 
data indicate that 40% calcineurin inhibition is achieved with 
voclosporin at an AUC of 226 ng*h/mL, but a 15% rise in Clinical Ophthalmology 2008:2(4) 697
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serum creatinine (the lower threshold of clinical signiﬁ  cance) 
occurs only at an voclosporin AUC of 3448 ng*h/mL 
(Figure 4) (Yatscoff et al 2002; Isotechnika, Inc., 2008).
LUMINATE clinical trials program
Study rationale and objective
Although a number of corticosteroid-sparing immunomodu-
latory agents have been utilized in the treatment of uveitis 
over the past 2 decades, voclosporin is the ﬁ  rst to enter into 
pivotal clinical trials for FDA-approval. This landmark 
program is being conducted in North America, Europe, and 
India, and will enroll over 500 patients.
The LUMINATE program comprises three randomized, 
double-blind, placebo-controlled, phase 2/3 trials in patients 
with noninfectious, sight-threatening uveitis that is active 
intermediate-, anterior and intermediate-, posterior-, or 
pan-uveitis (Study 1, LUMINATE Active); quiescent 
intermediate-, anterior and intermediate-, posterior-, or 
panuveitis in patients requiring systemic immunosuppresssion 
for disease control (Study 2, LUMINATE Mainte-
nance); or active anterior in patients requiring systemic 
immunosuppression for disease control (Study 3, LUMI-
NATE Anterior) (Protocol 1, 2, 3). The study designs and 
procedures are highly consistent with the corticosteroid-
tapering paradigm used widely in clinical practice.
Enrollment criteria
Table 1 summarizes selected inclusion and exclusion criteria 
for the three clinical trials. The primary enrollment criterion is 
the presence of noninfectious uveitis that is either uncontrolled 
despite systemic or periocular corticosteroid therapy, or that 
requires systemic or periocular corticosteroids and/or immu-
nosuppressive agents for control (Protocol 1, 2, 3; Protocols 
1–3 Amendments).
Study endpoints
The primary efﬁ  cacy assessments largely follow the SUN 
Working Group guidelines for measurement of ocular 
inﬂ  ammation in clinical trials (Jabs et al 2005). Table 2 
summarizes the primary and secondary endpoints for each 
study in the LUMINATE clinical trial program. The primary 
endpoint in LUMINATE Active is mean change from 
baseline in vitreous haze score, and in LUMINATE Ante-
rior, mean change from baseline in anterior chamber cells. 
In LUMINATE Maintenance, the primary endpoint is 
inﬂ  ammatory exacerbation, deﬁ  ned as a clinically signiﬁ  cant 
deterioration from baseline of at least 2 grades in vitreous haze 
score and/or anterior chamber cells, and/or a deterioration 
in visual acuity of at least +0.3 LogMAR (Protocol 1, 2, 3; 
Protocol 1–3 Amendments). As secondary endpoints, all 
three trials examine changes in corticosteroid use, visual 
acuity, and quality of life.
Study design/methodology
All studies are phase 2/3 prospective, multicenter, 
double-masked, placebo-controlled, parallel-group, 
randomized trials in patients  13 years of age. Enrollment at 
approximately 60 sites in North America, Europe, and India 
is expected to range from 100 for LUMINATE Anterior to 
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Table 1 Selected inclusion and exclusion criteria for the LUMINATE clinical trials program (Protocol 1, p. 22–24; Protocol 2, p. 22–25; 
Protocol 3, p. 20–23)
LUMINATE Active LUMINATE Maintenance LUMINATE Anterior
Selected inclusion criteria
Documented history of noninfectious 
intermediate-, anterior and 
intermediate-, posterior-,
or pan-uveitis
Diagnosis of noninfectious intermediate-, 
anterior and intermediate-, posterior-, or 
pan-uveitis of at least 3 months duration 
prior to enrollment, requiring treatment 
during that period to control intraocular 
inﬂ  ammatory disease and avoid sight-
threatening complications due to inﬂ  am-
mation
Documented history of noninfectious 
anterior-, anterior and intermediate-,
or pan-uveitis
Uncontrolled uveitis, evidenced by 
Grade 2+ or higher vitreous haze in at 
least one eye for  2 weeks prior to 
randomization
Minimum prescribed therapy upon 
enrollment is  1 of the following:
Uncontrolled uveitis, evidenced by Grade 2+ 
or higher anterior chamber cells in at least 
one eye for  2 weeks prior to randomization
Current uveitis therapy must conform 
to  1 of the following:
Systemic prednisone or equivalent 
averaging  10 mg/day
In subjects whose diagnosis is not 
exclusively anterior uveitis, the predominant 
manifestation of their condition at the time 
of enrollment must be anterior segment 
inﬂ  ammation
Prednisone monotherapy at a dose
of  10 mg/day (or equivalent) for  2 
weeks prior to randomization
Received  2 intravitreal/periocular 
corticosteroid administrations for control 
of inﬂ  ammatory disease within the past 
8 months, but not within 6 weeks of 
randomization
Current uveitis therapy must conform
to  1 of the following:
Received  2 injections of 
corticosteroid (intravitreal or 
periocular) for control of disease 
within the past 8 months, but not 
within 2 weeks of randomization; 
subjects may be receiving systemic 
corticosteroids
Note: Subjects may be receiving topical corti-
costeroids for control of anterior inﬂ  ammation 
during study
Prednisone monotherapy at a dose
of  10 mg/day (or equivalent) for  2 weeks 
prior to randomization
Subjects for whom corticosteroid 
therapy (oral or systemic) is medically 
inappropriate, or who refuse 
corticosteroid therapy
Subjects with clinically quiescent uveitis 
in both eyes at enrollment and who have 
been on a treatment regimen that has 
neither been intensiﬁ  ed nor augmented for 
a minimum of 6 weeks
Received  2 injections of corticosteroid 
(intravitreal or periocular) for control of 
disease within the past 8 months, but not 
within 2 weeks of randomization; subjects may 
be receiving systemic corticosteroids
Subjects who do not plan to undergo 
elective ocular surgery (eg, cataract 
extraction) during study
Considered by the investigator to require 
immunomodulatory therapy
Subjects for whom corticosteroid therapy 
(oral or systemic) is medically inappropriate, 
or who refuse corticosteroid therapy
A minimum ability to count ﬁ  ngers at 
a distance of 1 meter, 30 centimeters 
using the study eye
Must have best corrected visual acuity 
(BCVA) in the worst involved eye of 
20/400 or better (Early Treatment Diabetic 
Retinopathy Study [ETDRS] logMAR 
 1.34)
Subjects who do not plan to undergo elective 
ocular surgery (eg, cataract extraction) during 
study
Considered by the investigator to 
require immunomodulatory therapy
Subjects who do not plan to undergo 
elective ocular surgery (eg, cataract 
extraction) during study
A minimum ability to count ﬁ  ngers at a 
distance of 1 meter, 30 centimeters using the 
study eye
Must be  13 years of age and must 
weigh at least 38 kg (84 lbs) and no 
more than 110 kg (242 lbs)
Must be  13 years of age and must weigh 
at least 38 kg (84 lbs) and no more than 
110 kg (242 lbs)
Considered by the investigator to require 
immunomodulatory therapy
Must be  13 years of age and must weigh at 
least 38 kg (84 lbs) and no more than 110 kg 
(242 lbs)
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approximately 210 and 220, respectively, for LUMINATE 
Active and LUMINATE Maintenance. In each study, patients 
will be randomized in a 2:2:2:1 ratio to 1 of 4 treatments: 
voclosporin at a dose of 0.2, 0.4, or 0.6 mg/kg bid, or placebo 
(Protocol 1, 2, 3).
Patients will be assessed at baseline and at weeks 2, 4, 
8, 12, 16, 20, and 24 with an optional 24 week extension 
in the LUMINATE Active and Anterior studies; in the 
LUMINATE Maintenance study, assessments will be 
made at baseline and at weeks 2, 6, 10, 14, 18, 22, and 
26 with an optional 24 week extension. Assessments 
include best corrected visual acuity, slit lamp exam and 
tonometry, dilated fundus exam, graded assessments of 
vitreous haze and AC cells, quality of life, and selected 
Table 1 (Continued)
LUMINATE Active LUMINATE Maintenance LUMINATE Anterior
Selected exclusion criteria
Uveitis of infectious etiology √√ √
Clinically suspected or conﬁ  rmed 
central nervous system or ocular 
lymphoma
√√ √
Primary diagnosis of anterior uveitis √√
Uncontrolled glaucoma, evidenced 
by an intraocular pressure 
of  21 mmHg while on medical 
therapy, and chronic hypotony 
( 6 mmHg)
√√ √
Presence of an ocular toxoplasmosis 
scar
√√ √
Any implantable corticosteroid-eluting 
device (eg, Retisert™, Posurdex®, 
Medidur™, I-vation™ TA intravitreal 
implant)
√√ √
Treatment with an immune 
suppression regimen that includes an 
alkylating agent within the previous 
90 days
√√ √
Treatment with a monoclonal 
antibody or any other biologic 
therapy within the previous 30 days, 
or with alemtuzumab within the 
previous 12 months
√√ √
Use of any drugs or substances 
known to be strong inhibitors of CYP 
3A4/5 enzymes within 7 days of the 
ﬁ  rst dose, or grapefruit juice and star 
fruit within 24 hours of the ﬁ  rst dose
√√ √
Lens opacities or obscured ocular 
media upon enrollment such that 
reliable evaluations and grading of 
the posterior segment cannot be 
performed
√√
Evidence of active, uncontrolled 
noninfectious uveitis
√
History or diagnosis of Behçet’s 
disease
√
Local (periocular/intravitreal) 
administration of corticosteroids 
within the previous 6 weeks
√Clinical Ophthalmology 2008:2(4) 700
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Table 2 Primary, secondary, and additional endpoints of the LUMINATE clinical trial program* (Protocol 1, p. 18; Protocol 2, p. 18; 
Protocol 3, p. 17)
LUMINATE Active LUMINATE Maintenance LUMINATE Anterior
Primary endpoints
Mean change from baseline in graded 
vitreous haze after 16 weeks of therapy or at 
time of rescue, if earlier
Mean change from baseline in graded 
vitreous haze after 24 weeks of therapy or at 
time of rescue, if earlier
The proportion of subjects experiencing 
inﬂ  ammatory exacerbation during 26 weeks of 
treatment, as deﬁ  ned by a clinically signiﬁ  cant 
deterioration in either eye for one or more of the 
following:
•   Vitreous haze: increase of  2 grades from 
baseline
•   AC cells: increase of  2 grades from baseline
•   Visual acuity: change of   + 0.3 logMAR from 
baseline in BCVA
Mean change from baseline in graded 
AC cells after 16 weeks of therapy or 
at time of rescue, if earlier
Mean change from baseline in graded 
AC cells after 24 weeks of therapy or 
at time of rescue, if earlier
Secondary and additional endpoints
Proportion of subjects tapered to  5 mg/day 
of prednisone (or equivalent) by Week 16, 
and who do not require intensiﬁ  cation or 
augmentation of therapy through Week 24
Change from baseline in dose of oral corticosteroid 
at week 26 or at time of rescue, if earlier
Proportion of subjects tapered 
to  5 mg/day of prednisone (or 
equivalent) by Week 16, and who do 
not require intensiﬁ  cation or augmen-
tation of therapy through Week 24
Mean change from baseline in BCVA using 
the ETDRS method at week 24 or subject’s 
last visit, if earlier
Change from baseline in BCVA at week 26 or at 
time of rescue, if earlier
Mean change from baseline in graded 
vitreous haze after 16 and 24 weeks 
of therapy or at time of rescue, if 
earlier, in the subset of subjects 
entering the study with a diagnosis 
of either panuveitis or anterior and 
intermediate uveitis
Mean change from baseline in thickness of 
the macula, as measured by OCT, at Week 24 
or at subject’s last visit, if earlier
Change from baseline in QoL, NEI VFQ-25, EQ-5D, 
and SF-36, at week 26 or at time of rescue, if earlier
Mean change from baseline in 
BCVA using the ETDRS method at 
24 weeks of therapy or at time of 
rescue, if earlier
Mean change from baseline in graded AC cells 
after 16 weeks of therapy or at time of 
rescue, if earlier, in the subset of subjects 
entering the study with a diagnosis of either 
panuveitis or anterior and intermediate uveitis
Time to occurrence of deterioration from baseline 
of  2 grades of vitreous haze during 26 weeks of 
therapy
Change from baseline in QoL, 
NEI VFQ-25, EQ-5D, and SF-36
Mean change from baseline in graded AC cells 
after 24 weeks of therapy or at time of 
rescue, if earlier, in the subset of subjects 
entering the study with a diagnosis of either 
panuveitis or anterior and intermediate uveitis
Time to occurrence of deterioration from baseline 
in graded AC cells during 26 weeks of therapy 
in the subset of patients entering the study with 
a diagnosis of either panuveitis or anterior and 
intermediate uveitis
Change from baseline in thickness of 
macula at 24 weeks of therapy or at 
time of rescue, if earlier, as conﬁ  rmed 
by OCT
Mean change from baseline in daily 
prednisone dose at 24 weeks or at time of 
rescue, if earlier
Time to occurrence of inﬂ  ammatory exacerbation 
during 26 weeks of therapy
Mean change from baseline in graded 
AC ﬂ  are at 16 and 24 weeks of 
therapy or at time of rescue, if earlier
Mean change from baseline in thickness of 
the macula, as measured by OCT, at   Week 16
Extension of an existing lesion and/or occurrence 
of new lesions requiring treatment
Change from baseline in area of macular 
hyperﬂ  uorescence as measured by FA
Change from baseline in QoL, NEI VFQ-25, 
EQ-5D, and SF-36
Change from baseline in presence and/or 
severity of ocular exam inﬂ  ammatory 
abnormalities
Note: *All relevant measures in each study will be analyzed for the other eye.
Abbreviations: AC, anterior chamber; BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; EQ-5D, EuroQoL-5 domains; FA, ﬂ  uorescein 
angiography; NEI VFQ-25, National Eye Institute Visual Functioning Questionnaire; OCT, optical coherence tomography; QoL, quality of life; SF-36, 36-Item Short Form Health 
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laboratory assessments that include CBC with differential, 
serum chemistry, lipid proﬁ  le, and renal and liver function 
tests. Optical coherence tomography will be performed 
in the LUMINATE Active and Anterior studies while 
ﬂ  uorescein angiography will be performed only in the 
former. Endothelial cell density (ECD) will be measured 
as a safety parameter in the LUMINATE Maintenance 
study (Protocols 01, 02, 03 – p12). All three trials include 
a standardized algorithm for tapering systemic and topical 
corticosteroids (Protocol 1, 2, 3).
Study treatment will be discontinued and rescue therapy 
administered if (1) patients with active noninfectious 
uveitis experience either a deterioration of at least 1 
grade in vitreous haze or AC cells at week 4 or show no 
improvement from baseline by week 8, or (2) patients with 
quiescent noninfectious uveitis experience a study end-
point (ie, inﬂ  ammatory exacerbation) (Protocol 1, 2, 3).
Rationale for dose selection
Preclinical and clinical data suggest that approximately 
50% calcineurin inhibition (achieved with voclosporin 
at a dosage of 0.4 mg/kg bid) leads to a meaningful 
clinical effect (Aspeslet et al 2004; Gupta et al 2006). 
This was demonstrated in a recently conducted random-
ized double-blind placebo-controlled study of patients 
with plaque psoriasis in which voclosporin (0.4 mg/kg 
bid) produced 50% calcineurin inhibition and proved 
to be both effective and well tolerated. A dosage 
of 0.2 mg/kg in that study was associated with 30% 
calcineurin inhibition and found to be subtherapeutic 
(Gupta et al 2006; Langley et al 2006).
PK/PD modeling of calcineurin inhibition suggests 
that bracketing the 0.4 mg/kg bid dosage with dosages of 
0.2 mg/kg bid and 0.6 mg/kg bid would offer a sufﬁ  ciently 
wide interval for dose ranging, resulting in approximately 
30% to 70% calcineurin inhibition (Protocol 1, 2, 3). This 
dose ranging will allow investigation of any correlation 
between the amount of drug administered and the impact 
on various parameters of uveitis (eg, inﬂ  ammation, macular 
thickening) and, ultimately, on clinical efﬁ  cacy.
Additional protocol features
Optical coherence tomography
The potential effect on retinal macular thickness by 
voclosporin will be evaluated by means of optical coherence 
tomography (OCT) in the LUMINATE Active and Anterior 
studies. Baseline measurement in addition to measurements 
over the course of the trials will be undertaken.
Fluorescein angiography
Macular hyperfluorescence will be evaluated in the 
LUMINATE Active study as assessed by fluorescein 
angiography.
Quality of life
Assessments will be performed in the LUMINATE program 
to examine the potential effect of treatment of uveitis with 
voclosporin on quality of life (QoL). Among the instru-
ments to be used are the National Eye Institute Visual 
Functioning Questionnaire, the Euro QoL-5, and the Short 
Form Health Survey.
Conclusions: Potential impact 
of LUMINATE ﬁ  ndings
The LUMINATE program possesses several unique design 
features that will make it a landmark among clinical trials 
of uveitis therapies. It is the ﬁ  rst pivotal-stage program 
undertaken for marketing approval of a corticosteroid-sparing 
agent for the treatment, control, and maintenance of all 
forms of noninfectious uveitis. It is also the ﬁ  rst program to 
examine the correlation between dose and effects on vari-
ous parameters of uveitis, including inﬂ  ammation, vision, 
macular thickness, and angiographic changes.
If the LUMINATE program is successful, voclosporin 
will become the ﬁ  rst steroid-sparing immunosuppressive 
drug approved by the FDA for the treatment of uveitis.
These ﬁ  ndings could have signiﬁ  cant implications for other 
ophthalmic diseases that are characterized by inﬂ  ammatory 
mechanisms (eg, dry eye syndrome, age-related macular degen-
eration, and diabetic retinopathy) and vascular leakage (eg, age-
related macular degeneration and diabetic macular edema).
In summary, if voclosporin proves to be an effective 
and safer treatment for noninfectious uveitis, inﬂ  ammation 
will be controlled, visual acuity will be maintained, and the 
need to take corticosteroids will be reduced or eliminated. 
Voclosporin could thus represent a new standard of care 
offering hope for patients with this devastating condition.
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